Martyn Davies, co-founder of Juniper Pharma Services and Emeritus Professor at the School of Pharmacy within The University of Nottingham, has been appointed as a Commander of the Order of the British Empire (CBE) in Her Majesty’s 2018 New Year’s Honours List.
Medal award
This prestigious award has been granted in recognition of Davies’ contribution to UK science and achievements in pharmaceutical research and drug development.
“Receiving a letter in the post notifying me of a CBE was a real shock but a wonderful surprise. I am extraordinarily honoured and genuinely humbled by this award,” Davies said. “I have loved my work in scientific research and translating this into pharmaceutical development. I am lucky that I have been able to train and work with many incredibly talented young scientists and also see their careers flourish. The UK is a world leader in pharmaceutical research and innovation and it has been so rewarding over the years to work in this field.
“This would not be possible without the contribution of those that have supported me on my professional journey that began 40 years ago. This award is testament to my colleagues at Juniper and at the School of Pharmacy at The University of Nottingham, and the support from my incredible family."
Robert Langer, David H. Koch Institute Professor at Massachusetts Institute of Technology, described the appointment as ‘such a wonderful honour’. He stated: “Martyn has done so much to advance pharmaceutical science across the world and is a wonderful human being as well.”
“We are extremely proud of Martyn as he receives this incredible honour,” commented Alicia Secor, president and chief executive officer at Juniper Pharmaceuticals. “It is richly deserved given his consistently excellent academic and commercial contribution to drug research and pharmaceutical product development and the remarkable contribution he has made to the industry.”
Davies co-founded Molecular Profiles (now Juniper Pharma Services) in 1997 and has played a significant role in the CDMO’s rapid growth and expansion over the last 20 years having worked on several hundred products, including over half of the world’s top 20 blockbuster drugs. In 2013, the company was acquired by Columbia Laboratories (now Juniper Pharmaceuticals).